Evidence map›Paper›PMID 29344091›Full record

ArticleTherapeutic advances in urology2018

The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Reza Mehrazin, Essel Dulaimi, Robert G Uzzo, Karthik Devarjan, Jianming Pei, Marc C Smaldone, Alexander Kutikov, Joseph R Testa, Tahseen Al-Saleem

Abstract read
In one paragraph

Article in Therapeutic advances in urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Reza MehrazinDepartment of Urology and Oncological Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Essel DulaimiDivisions of Pathology and Cancer Biology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Robert G UzzoDivisions of Urologic Oncology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Karthik DevarjanDivisions of Biostatistics; Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Jianming PeiDivisions of Pathology and Cancer Biology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Marc C SmaldoneDivisions of Urologic Oncology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Alexander KutikovDivisions of Urologic Oncology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Joseph R TestaDivisions of Pathology and Cancer Biology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.
Tahseen Al-SaleemDivisions of Pathology and Cancer Biology, Fox Chase Cancer Center-Temple Health System, Philadelphia, PA, USA.

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
NCI NIH HHS P30 CA006927
6 · The paper itself

Abstract

backgroundThe proto-oncogene

methodsCytogenetic analysis by conventional or Chromosomal Genomic Microarray Analysis (CMA) was performed on 414 renal tumors. Nonclear and nonpapillary RCC were excluded. Impact of gain in chromosome 8q status on CSM, OS, and its correlation with clinicopathological variables were evaluated. CSM and OS were assessed using log-rank test and the Cox proportional hazards model.

resultsA total of 297 RCC tumors with cytogenetic analysis were included. Gain of 8q was detected in 18 (6.1%) tumors (9 clear cell and 9 papillary RCC), using conventional method (

conclusionChromosome 8q harbors the proto-oncogene

Indexed as

8qc-MYCcytogenetic analysisprognosisproto-oncogenerenal cell carcinoma

Identifiers

PMID29344091
PMCPMC5761913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.